Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis
dc.contributor.author | Tombal, BF | |
dc.contributor.author | Loriot, Y | |
dc.contributor.author | Saad, F | |
dc.contributor.author | McDermott, RS | |
dc.contributor.author | Elliott, Tony | |
dc.contributor.author | Rodriguez-Vida, A | |
dc.contributor.author | Nole, F | |
dc.contributor.author | Fournier, B | |
dc.contributor.author | Collette, L | |
dc.contributor.author | Gillessen, Silke | |
dc.date.accessioned | 2019-11-19T16:01:08Z | |
dc.date.available | 2019-11-19T16:01:08Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol. 2019;37(15_suppl):5007-. | en |
dc.identifier.doi | 10.1200/JCO.2019.37.15_suppl.5007 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622470 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5007 | en |
dc.title | Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Universit� Catholique de Louvain, Brussels, Belgium | en |
dc.identifier.journal | Journal of Clinical Oncology | en |